Categories
Change Password!
Reset Password!
Vismodegib, a kinase inhibitor can offer
long-term safety in locally advanced basal cell carcinoma.
The outcomes of a recent study states, the FDA-approved
vismodegib to be safe and effective in patients with locally advanced basal
cell carcinoma (laBCC) thereby confirming its
transferability to daily clinical routine.
The uncontrolled cell proliferation from several epidermal
compartments can give way to basal cell carcinoma (BCC). This non-interventional
study by R Gutzmer et al. aimed to evaluate the safety and effectiveness of
vismodegib exclusively on the duration of response (DOR), for treatment of
laBCC.
Sixty-six patients
with a minimum of one dose of vismodegib were recruited and documented
retrospectively and/or prospectively for about 3 years. DOR was considered as
the primary efficacy variable. The use of
vismodegib, decision makers for therapy and technique of tumor response
assessment
were the exploratory variables.
The objective response rate
was 74.2% and the disease control rate was 90.9% with a median DOR being 15.9
months. The median progression-free survival and time to response were
19.1 and 2.7 months, respectively.
With no new new safety signals, 340
adverse events were described
in 63 (95.5%) patients.
Journal of the European Academy of Dermatology and Venereology
Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real world conditions in Germany - the non-interventional study NIELS
R Gutzmer et al.
Comments (0)